These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study.
    Author: Espié M, Mares P, de Reilhac P, Chevallier T, Daurès JP.
    Journal: Gynecol Endocrinol; 2006 Aug; 22(8):423-31. PubMed ID: 17012103.
    Abstract:
    OBJECTIVES: To determine breast cancer prevalence in postmenopausal women with or without hormone replacement therapy (HRT). PATIENTS AND METHODS: This was a historical-prospective study with random patient selection. Patients were recruited between January 2004 and February 2005, and allocated to two groups: the 'treated group' comprising postmenopausal women on HRT regimens commonly prescribed in France or who had stopped <5 years previously; or the 'untreated group' of postmenopausal women who had never received HRT or stopped >5 years previously. RESULTS: In total 6755 patients fulfilled all inclusion criteria: 3383 in the treated group and 3372 in the untreated group. The treated group was younger and less overweight than the untreated group (p < 0.0001). The treated group had fewer late menopauses (p = 0.0002) and fewer first-degree family histories of breast cancer (p < 0.0001). Mean HRT duration was 7.9 years; 30.5% of women were treated for >or=10 years. Breast cancer prevalence was 1.01% for the treated group and 6.21% for the untreated group. The European standardized incidence rate of breast cancer in the untreated group was significantly higher than in the French reference population (comparative incidence figure ratio (CIFR) = 2.24; 95% confidence interval (CI) = 1.50-3.36). In contrast, the European standardized incidence rate in the treated group on the studied HRT regimens (excluding some progestins) was not significantly different from that of the reference population (CIFR = 1.04; 95% CI = 0.35-3.15). CONCLUSION: The differences between the two groups may be due to French gynecologists' treatment strategy of avoiding prescribing HRT to high-risk women, and also perhaps to a specific 'studied HRT' effect.
    [Abstract] [Full Text] [Related] [New Search]